RxDoctor Payments Data

Min Kyu Han, MD

Ophthalmology · Peoria, ILNPI 1912901877

Payments from drug & device makers

What this record shows

This record is dominated by grants: $7,140 of the $8,460 with a category attached, or 84.4%. AbbVie accounts for 87.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $7,445, more than ten times the $201 reported in 2019.

$8,460in general payments, 2019–2025

Across 42 payments — averaging $201.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Bausch & Lomb Americas Inc.$296
  • Genentech USA, Inc.$214
  • Apellis Pharmaceuticals, Inc.$91
  • Novartis$89
  • Carl Zeiss Meditec, Inc.$88
  • plus $267 from 5 others
$42,459in research payments, 2019–2025

Across 15 payments — averaging $2830.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$42K

What the payments were for

  • Grants$7,14084%
  • Food & beverage$1,32016%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,460 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois →

Medicare billing

Part B allowed, 2024
$7,193,617
Medicare patients
1,289
Services billed
144,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate374$15,435
LumiganBimatoprost11$3,644
Ketorolac Tromethamine201$2,758
Latanoprost86$715
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$520
Timolol Maleate63$435
Brimonidine Tartrate19$196
Dorzolamide Hcl17$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$7,415$3,64411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Peoria

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →